Liquidia Co. (NASDAQ:LQDA) Insider Jason Adair Sells 1,833 Shares

Liquidia Co. (NASDAQ:LQDA) insider Jason Adair sold 1,833 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $11.44, for a total transaction of $20,969.52. Following the transaction, the insider now directly owns 113,393 shares of the company’s stock, valued at $1,297,215.92. The sale was disclosed in a document filed with the SEC, which is available through this link.

Jason Adair also recently made the following trade(s):

• On Monday, June 3rd, Jason Adair sold 455 shares of Liquidia stock. The stock was sold at an average price of $14.55, for a total transaction of $6,620.25.

Liquidia Trading Down 0.2 %

LQDA stock traded down $0.02 during trading on Monday, hitting $11.61. The company had a trading volume of 445,156 shares, compared to its average volume of 884,034. The business has a 50 day moving average of $12.57 and a 200 day moving average of $13.40. The firm has a market capitalization of $887.17 million, a price-to-earnings ratio of -7.46 and a beta of 0.32. Liquidia Co. has a fifty-two week low of $5.71 and a fifty-two week high of $16.99.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.22). Liquidia had a negative net margin of 674.42% and a negative return on equity of 177.83%. The company had revenue of $2.97 million during the quarter, compared to the consensus estimate of $4.31 million. As a group, equities analysts predict that Liquidia Co. will post -1.32 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on LQDA. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Liquidia in a report on Wednesday, July 10th. Oppenheimer started coverage on shares of Liquidia in a research note on Tuesday, June 25th. They set a “market perform” rating for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of Liquidia in a research note on Thursday, July 18th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Liquidia has an average rating of “Moderate Buy” and an average target price of $21.60.

Institutional Trading of Liquidia

Institutional investors have recently modified their holdings of the company. Hilltop National Bank acquired a new position in Liquidia during the second quarter worth about $33,000. Tower Research Capital LLC TRC grew its stake in shares of Liquidia by 610.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,997 shares of the company’s stock worth $108,000 after purchasing an additional 7,731 shares during the last quarter. DMC Group LLC bought a new stake in shares of Liquidia in the 2nd quarter worth approximately $122,000. Whitcomb & Hess Inc. acquired a new stake in Liquidia during the second quarter valued at approximately $126,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Liquidia by 398.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,039 shares of the company’s stock valued at $156,000 after purchasing an additional 10,421 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).